RAVASIO, R.; CRANMER, H.; KEARNS , I.; VITI, R.; CORINTI, S. Cost-utility analysis of brigatinib compared to alectinib in the treatment of ALK-positive NSCLC in patients previously not treated with an ALK inhibitor. AboutOpen, [S. l.], v. 9, n. 1, p. 92–104, 2022. DOI: 10.33393/ao.2022.2450. Disponível em: https://journals.aboutscience.eu/index.php/aboutopen/article/view/2450. Acesso em: 29 mar. 2024.